IP Library Granted Patent US 12,473,252
Granted Patent B2
US 12,473,252 · App. 18/765,881 · Granted Nov 18, 2025

Processes for the preparation of deuterated D-serine

Inventors: Adam Morgan (Ashland, MA); Robert S. Lewis (Lexington, MA)
Assignee: Sun Pharmaceutical Industries, Inc.
C07C227/32C07D263/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,252
App. No.
18/765,881
Granted
Nov 18, 2025
Kind
B2
Abstract

Disclosed are methods for preparing deuterated analogs of D -serine and compounds useful for preparing deuterated analogs of D -serine.

Claims (51)

1 . A method for preparing D -serine-2-d,

the method comprising:

contacting a compound of Formula E;

wherein

R 2 is C 1 -C 6 alkyl; and

R 3 is H, D, or a protecting group,

with acid under conditions suitable for opening of the oxazolidine ring;

and optionally removing the R 3 protecting group in the same or in a separate step as the contacting step, such that D -serine-2-d is formed;

wherein the D -serine-2-d has a deuterium incorporation of at least 95% at the position specified as deuterium.

2 . The method of claim 1 , wherein R 2 is isopropyl or t-butyl.

3 . The method of claim 1 , wherein R 3 is a protecting group selected from —C(O)H, —C(O)—X—C 1 -C 6 alkyl, —C(O)—X—C 3 -C 6 cycloalkyl, —C(O)—X—CH 2 -aryl, —C(O)—X-aryl, and —CH 2 -aryl, wherein X is absent, O, NH, or S.

4 . The method of claim 1 , wherein the compound of Formula E is selected from the group consisting of:

5 . The method of claim 1 , wherein the method further comprises, prior to the step of contacting the compound of Formula E with an acid, the steps of:

(i) contacting a compound of Formula B:

wherein

[R 1 ] R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —CH 2 -aryl, or aryl;

R 2 is C 1 -C 6 alkyl; and

R 3 is H, D, or a protecting group,

with a base to form a first reaction mixture;

(ii) contacting the first reaction mixture with a deuterium source to form a second reaction mixture under conditions such that the compound of structure (D) is formed:

wherein R 1 , R 2 and R 3 are as defined for the compound of Formula (B);

and

(iii) contacting the second reaction mixture with a base to form the compound of Formula E, wherein the compound of Formula E has a deuterium incorporation of at least 95% at each position specified as deuterium.

6 . The method of claim 4 , wherein the acid is HCl.

7 . The method of claim 5 , wherein the compound of Formula E is compound 50:

8 . The method of claim 5 , wherein the step of contacting the second reaction mixture with a base comprises contacting the second reaction mixture with 1-10 equivalents of lithium deuteroxide.

9 . A compound represented by the structure (E):

wherein

R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or aryl; and

R 3 is H, D, —C(O)H, —C(O)—X—C 1 -C 6 alkyl, —C(O)—X—C 3 -C 6 cycloalkyl, —C(O)—X—CH 2 -aryl, —C(O)—X-aryl, or —CH 2 -aryl, wherein X is absent, O, NH, or S;

wherein the compound has a deuterium incorporation of at least 90% at the position specified as deuterium.

10 . The compound of claim 9 , wherein

R 3 is H, D, —C(O)—X—C 1 -C 6 alkyl, —C(O)—X—C 3 -C 6 cycloalkyl, or —C(O)—X-aryl, wherein X is absent, O, NH, or S.

11 . A method for preparing a compound represented by the structure (D):

wherein

R 1 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —CH 2 -aryl, or aryl;

R 2 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or aryl; and

R 3 is H, D, or a protecting group;

wherein the compound has a deuterium incorporation of at least 90% at the position specified as deuterium,

the method comprising the steps of:

contacting a compound represented by the structure (B)

 in which R 1 , R 2 , and R 3 are as defined for the compound of Formula (D);

 with a base to form a reaction mixture; and

 contacting the reaction mixture with at least 1 equivalent of a deuterium source;

under conditions such that the compound of structure (D) is formed;

wherein the compound of structure (D) has a deuterium incorporation of at least 90% at the position specified as deuterium.

12 . The method of claim 11 , wherein the base is selected from mesityllithium, 2,6-dimethoxyphenyllithium, 2,4,6-trimethoxyphenyllithium, tolyllithium, t-butyllithium, phenyllithium, lithium hexamethyldisilazide (LHMDS) and tritylsodium.

13 . The method of claim 11 , wherein the deuterium source is D 2 O.

14 . The method of claim 11 , wherein the step of contacting the reaction mixture with at least 1 equivalent of a deuterium source comprises contacting the reaction mixture with 1-10 equivalents of the deuterium source.

15 . The compound of claim 9 , wherein the compound has a deuterium incorporation of at least 95% at the position specified as deuterium.

16 . The method of claim 11 , wherein the compound of structure (D) has a deuterium incorporation of at least 95% at the position specified as deuterium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2024
From: MORGAN, ADAM; LEWIS, ROBERT S.
To: CONCERT PHARMACEUTICALS, INC.
Reel/Frame 068075/0764 →
MERGER Recorded Jul 24, 2024
From: CONCERT PHARMACEUTICALS, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 068075/0824 →
Continuity (3)
Continuation 17601348
Provisional Application 62828884 · Apr 3, 2019
Related Publication 20250042841A1 · Feb 6, 2025
References Cited (39)
US 4582931A · Grabowski et al. · 1986 [cited by applicant]
US 6221335B1 · Foster · 2001 [cited by applicant]
US 6440710B1 · Keinan et al. · 2002 [cited by applicant]
US 6603008B1 · Ando et al. · 2003 [cited by applicant]
US 7517990B2 · Ito et al. · 2009 [cited by applicant]
US 10668036B2 · Doller et al. · 2020 [cited by applicant]
US 12065395B2 · Morgan · 2024 [cited by examiner]
US 20070082929A1 · Gant et al. · 2007 [cited by applicant]
US 20070197695A1 · Potyen et al. · 2007 [cited by applicant]
US 20080103122A1 · Veltri · 2008 [cited by applicant]
WO WO199526325A2 · 1995 [cited by applicant]
WO WO2007118651A1 · 2007 [cited by applicant]
WO WO2019104179A1 · 2019 [cited by applicant]
Anson, M.S. et al., Org. Process Res. Dev., “Complementary Syntheses of N,O-Protected-(S)-2-methylserine on a Multikilogram Scale,” 2011, 15:389-397. [cited by applicant]
Baillie, T. A., “The Use of Stable Isotopes in Pharmacological Research,” Pharmacological Reviews, 33(2): 81-132 (1981). [cited by applicant]
Blake et al., “Studies with Deuterated Drugs,” J Pharm Sci, 1975, 64:367-391. [cited by applicant]
Browne, T. R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,” J. Clin. Pharmacol., 38: 213-220 (1998). [cited by applicant]
Brunner, “Stereocontrolled a-Alkylation of Fully Protected L-Serine,” Eur. J. Org. Chem. 2004, p. 3879-3883. [cited by applicant]
Cherrah, Y., et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,” Biomedical and Environmental Mass Spectrometry, 14: 653-657 (198… [cited by applicant]
Dyck, L. E., et al., “Effects of Deuterium Substitution on the Catabolismof β-Phenylethylamine: An In Vivo Study,” Journal of Neurochemistry, 46(2): 399-404 (1986). [cited by applicant]
Fisher, M.B. et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-Mediated Metabolism,” Curr. Opin. Drug Discov. Devel., 9(1):101-109 (2006). [cited by applicant]
Foster, A. B., “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends in Pharmacological Sciences, 5: 524-527 (1984). [cited by applicant]
Foster, A. B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,” Advances in Drug Research, 14: 1-40 (1985). [cited by applicant]
Fukuto, et al., Determination of the Mechanism of Demethylenation of (Methylenedioxy)phenyl Compounds by Cytochrome P450 Using Deuterium Isotope Effects, J Med Chem, 1991, 34:2871-2876. [cited by applicant]
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,” Biomedical and Environmental Mass Spectrometry, 15: 243-247 (1988). [cited by applicant]
Greene, “N-Benzylamine” Greene's Protective Groups in Organic Synthesis, 2007, p. 814-818. [cited by applicant]
Hashimoto, A. et al.: “Effect of systemic administration of D-serine on the levels of D- and L-serine in several areas and periphery of rat,” European Jpournal of Pharmacology, Jul. 14, 2004, 495(2-3):153-8. [cited by applicant]
Haskins, N. J., “The Application of Stable Isotopes in Biomedical Research,” Biomedical Mass Spectrometry, 9(7): 269-277 (1982). [cited by applicant]
Honma S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride,” Drug Metabolism and Disposition, 15(4): 551-559 (1987). [cited by applicant]
Iio, Y. et al., “Asymmetric Synthesis of a, apDisubstituted a-Amino Alcohol Derivatives,” Tet. Asymm. 22:323-328 (2011). [cited by applicant]
International Preliminary Report on Patentability in Appln. No. PCT/US2020/026739, dated Sep. 28, 2021, 9 pages. [cited by applicant]
International Search Report and Written Opinion in Appln. No. PCT/US2020/26739, dated Jun. 19, 2020, 11 pages. [cited by applicant]
Kushner, D.J. et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,” Can. J. Physiol. Pharmacol., 77:79-88 (1999). [cited by applicant]
Loh, T-P et. al.: “Synthetic Studies Towards Kaitocephalin”, Tetrahedron Letters, 42:7893-7897, 2001. [cited by applicant]
Pieniaszek, H. J., et al., “Moricizine Bioavailability via Simultaneous, Dual, Stable Isotope Administration: Bioequivalence Implications,” J. Clin. Pharmacol, 39: 817-825 (1999). [cited by applicant]
Reider, P.J., et al., “Synthesis of (R)-Serine-2-d and Its Conversion to the Broad Spectrum Antibiotic Fludalanine,” J. Org. Chem. 52:3326-3334 (1987). [cited by applicant]
Seebach, D., Aebi, J.D., “Alpha-Alkylation of Serine With Self-Reproduction of the Center of Chirality,” Tet. Lett.25(24):2545-2548 (1984). [cited by applicant]
Tonn G. R., et al., “Simultaneous Analysis of Diphenhydramine and a Stable Isotope Analog (2H10) Diphenhydramine Using Capillary Gas Chromatography with Mass Selective Detection in Biological Fluids from Chronically Ins… [cited by applicant]
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,” J. Clin. Pharmacol., 26: 419-424 (1986). [cited by applicant]